Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s ...

Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

A larger pharma company may decide it's worth taking Viking's promising drug candidate through phase 3.

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $32.37, demonstrating a +2.65% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.58%.

River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...

Viking Holdings Ltd.'s stock is set to receive a warm welcome on Wall Street, as the Berumda-based cruise operator goes public. The company's initial public offering of 53 million shares priced at $24 ...

Across the recent three months, 10 analysts have shared their insights on Viking Holdings (NYSE: VIK ), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll ...

Investing.com -- Mizuho initiated coverage of Viking Holding with an Underperform rating and $54 price target, saying the stock’s premium pricing leaves limited upside despite the company’s ...